6.44
price down icon1.08%   -0.07
after-market アフターアワーズ: 6.44
loading
前日終値:
$6.51
開ける:
$6.5
24時間の取引高:
580.54K
Relative Volume:
1.92
時価総額:
$321.15M
収益:
$36.90M
当期純損益:
$-166.28M
株価収益率:
-1.9574
EPS:
-3.29
ネットキャッシュフロー:
$-203.53M
1週間 パフォーマンス:
-20.20%
1か月 パフォーマンス:
-19.50%
6か月 パフォーマンス:
-17.22%
1年 パフォーマンス:
-73.93%
1日の値動き範囲:
Value
$6.19
$6.5433
1週間の範囲:
Value
$6.10
$8.11
52週間の値動き範囲:
Value
$6.10
$25.39

Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile

Name
名前
Bicycle Therapeutics Plc Adr
Name
セクター
Healthcare (1134)
Name
電話
011441223261503
Name
住所
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Name
職員
305
Name
Twitter
@Bicycle_tx
Name
次回の収益日
2025-08-08
Name
最新のSEC提出書
Name
BCYC's Discussions on Twitter

BCYC を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
BCYC
Bicycle Therapeutics Plc Adr
6.44 451.59M 36.90M -166.28M -203.53M -3.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
409.47 105.61B 11.74B 3.68B 3.50B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
657.53 67.99B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
442.70 58.19B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
854.65 52.40B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
189.70 39.60B 447.02M -1.18B -906.14M -6.1812

Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-31 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2024-11-08 開始されました Stephens Equal-Weight
2024-09-06 開始されました RBC Capital Mkts Outperform
2024-08-07 ダウングレード B. Riley Securities Buy → Neutral
2023-09-11 アップグレード B. Riley Securities Neutral → Buy
2022-08-31 開始されました Cowen Outperform
2022-07-28 開始されました Barclays Overweight
2022-07-06 再開されました Canaccord Genuity Buy
2022-04-13 ダウングレード B. Riley Securities Buy → Neutral
2022-04-07 再開されました Cantor Fitzgerald Overweight
2022-02-14 開始されました Morgan Stanley Equal-Weight
2021-12-17 開始されました SVB Leerink Outperform
2021-12-09 開始されました Needham Buy
2021-09-30 開始されました B. Riley Securities Buy
2021-04-20 開始されました JMP Securities Mkt Outperform
2020-10-12 開始されました Cantor Fitzgerald Overweight
2020-06-12 開始されました Oppenheimer Outperform
2020-04-17 開始されました H.C. Wainwright Buy
2019-11-14 開始されました ROTH Capital Buy
2019-09-11 アップグレード Goldman Neutral → Buy
2019-06-17 開始されました Canaccord Genuity Buy
2019-06-17 開始されました Goldman Neutral
2019-06-17 開始されました Jefferies Buy
2019-06-17 開始されました Piper Jaffray Overweight
すべてを表示

Bicycle Therapeutics Plc Adr (BCYC) 最新ニュース

pulisher
Nov 06, 2025

A new trading data show Bicycle Therapeutics Plc ADR (BCYC) is showing positive returns. - setenews.com

Nov 06, 2025
pulisher
Nov 04, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 8.8% Following Analyst Downgrade - MarketBeat

Nov 04, 2025
pulisher
Nov 04, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Down 8.8% After Analyst Downgrade - Defense World

Nov 04, 2025
pulisher
Nov 03, 2025

Pinnacle Associates Ltd. Sells 42,325 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Nov 03, 2025
pulisher
Nov 03, 2025

Analysts Set Expectations for BCYC Q1 Earnings - MarketBeat

Nov 03, 2025
pulisher
Nov 02, 2025

EBITDA per share of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView

Nov 02, 2025
pulisher
Nov 01, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap DownHere's Why - MarketBeat

Nov 01, 2025
pulisher
Oct 31, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 9.8% on Earnings Beat - MarketBeat

Oct 31, 2025
pulisher
Oct 31, 2025

Bicycle Therapeutics stock price target raised to $12 from $10 at Citizens By Investing.com - Investing.com South Africa

Oct 31, 2025
pulisher
Oct 31, 2025

RBC Capital downgrades Bicycle Therapeutics stock on delayed pipeline progress By Investing.com - Investing.com South Africa

Oct 31, 2025
pulisher
Oct 30, 2025

Bicycle Therapeutics earnings beat by $0.23, revenue topped estimates - Investing.com South Africa

Oct 30, 2025
pulisher
Oct 30, 2025

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results - Placera.se

Oct 30, 2025
pulisher
Oct 27, 2025

Bicycle Therapeutics PLC Sponsored ADR $BCYC Position Boosted by Tybourne Capital Management HK Ltd. - MarketBeat

Oct 27, 2025
pulisher
Oct 17, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 5.2%Here's Why - MarketBeat

Oct 17, 2025
pulisher
Oct 16, 2025

100,291 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Acquired by Janney Montgomery Scott LLC - Defense World

Oct 16, 2025
pulisher
Oct 16, 2025

Global X MLP & Energy Infrastructure ETF $MLPX Holdings Boosted by Janney Montgomery Scott LLC - Defense World

Oct 16, 2025
pulisher
Oct 15, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Receives “Sell (D-)” Rating from Weiss Ratings - Defense World

Oct 15, 2025
pulisher
Oct 12, 2025

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 12, 2025
pulisher
Oct 12, 2025

Analyzing Fractyl Health (NASDAQ:GUTS) & Plus Therapeutics (NASDAQ:PSTV) - Defense World

Oct 12, 2025
pulisher
Oct 12, 2025

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Oct 12, 2025
pulisher
Oct 10, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 10.5%What's Next? - MarketBeat

Oct 10, 2025
pulisher
Oct 06, 2025

Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 3,231 Shares - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells 2,263 Shares of Stock - MarketBeat

Oct 06, 2025
pulisher
Oct 03, 2025

Bicycle Therapeutics Sees Unusually Large Options Volume (NASDAQ:BCYC) - Defense World

Oct 03, 2025
pulisher
Oct 02, 2025

Stock Traders Purchase High Volume of Bicycle Therapeutics Call Options (NASDAQ:BCYC) - MarketBeat

Oct 02, 2025
pulisher
Sep 29, 2025

Goldman Sachs Group Inc. Takes Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World

Sep 29, 2025
pulisher
Sep 24, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 7.8%Here's Why - MarketBeat

Sep 24, 2025
pulisher
Sep 22, 2025

126,062 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Acquired by Acadian Asset Management LLC - MarketBeat

Sep 22, 2025
pulisher
Sep 20, 2025

Analysts Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Price Target at $22.22 - MarketBeat

Sep 20, 2025
pulisher
Sep 18, 2025

126,062 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Bought by Acadian Asset Management LLC - Defense World

Sep 18, 2025
pulisher
Sep 17, 2025

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Sep 17, 2025
pulisher
Sep 15, 2025

3 Stocks To Buy Under $10 That Could Triple From Here - Barchart.com

Sep 15, 2025
pulisher
Sep 11, 2025

Cubist Systematic Strategies LLC Sells 2,650 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World

Sep 11, 2025
pulisher
Sep 09, 2025

Bicycle Therapeutics appoints oncology veterans Dansey and Hoppenot to board - Investing.com India

Sep 09, 2025
pulisher
Sep 06, 2025

Caption Management LLC Sells 81,517 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Sep 06, 2025
pulisher
Sep 05, 2025

Armistice Capital LLC Has $22.69 Million Holdings in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Sep 05, 2025
pulisher
Sep 04, 2025

Long Focus Capital Management LLC Acquires 750,661 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Sep 04, 2025
pulisher
Sep 03, 2025

Bicycle Therapeutics PLC Sponsored ADR $BCYC Stock Holdings Cut by Tybourne Capital Management HK Ltd. - MarketBeat

Sep 03, 2025
pulisher
Aug 29, 2025

Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025 - GlobeNewswire Inc.

Aug 29, 2025
pulisher
Aug 27, 2025

Candriam S.C.A. Acquires 117,331 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Aug 27, 2025
pulisher
Aug 20, 2025

Analysts’ Weekly Ratings Updates for Bicycle Therapeutics (BCYC) - Defense World

Aug 20, 2025
pulisher
Aug 13, 2025

Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com

Aug 13, 2025
pulisher
Aug 13, 2025

Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress By Investing.com - Investing.com South Africa

Aug 13, 2025
pulisher
Aug 13, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Given New $13.00 Price Target at Morgan Stanley - Defense World

Aug 13, 2025
pulisher
Aug 08, 2025

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results - Placera.se

Aug 08, 2025
pulisher
Aug 01, 2025

Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? - MSN

Aug 01, 2025
pulisher
Jul 31, 2025

Rice Biotech Launch Pad adds TPG Life Sciences’ Carolyn Ng to board - Investing.com

Jul 31, 2025
pulisher
Jul 31, 2025

Should I buy Bicycle Therapeutics (BCYC) - Zacks Investment Research

Jul 31, 2025
pulisher
Jul 29, 2025

Coursera (NYSE:COUR) Sees Strong Trading Volume on Analyst Upgrade - Defense World

Jul 29, 2025
pulisher
Jul 17, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Teacher Retirement System of Texas - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Principal Financial Group Inc. Boosts Stock Position in Schneider National, Inc. (NYSE:SNDR) - Defense World

Jul 17, 2025

Bicycle Therapeutics Plc Adr (BCYC) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Bicycle Therapeutics Plc Adr (BCYC) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Lee Kevin
CHIEF EXECUTIVE OFFICER
Oct 02 '25
Sale
8.40
2,263
19,009
478,541
Skynner Michael
CHIEF TECHNOLOGY OFFICER
Oct 03 '25
Sale
8.41
978
8,225
118,277
Skynner Michael
CHIEF TECHNOLOGY OFFICER
Oct 02 '25
Sale
8.40
824
6,922
119,255
Milnes Alistair
CHIEF OPERATING OFFICER
Oct 02 '25
Sale
8.40
1,147
9,635
94,355
Milnes Alistair
CHIEF OPERATING OFFICER
Oct 03 '25
Sale
8.41
978
8,225
93,377
Hannay Michael Charles Ferguso
CHIEF PROD & SUPPLY CHAIN OFF
Oct 02 '25
Sale
8.40
473
3,973
53,352
Hannay Michael Charles Ferguso
CHIEF PROD & SUPPLY CHAIN OFF
Oct 03 '25
Sale
8.41
250
2,102
53,102
Young Alethia
Chief Financial Officer
Oct 02 '25
Sale
8.51
482
4,103
44,704
Thompson Travis Alvin
CHIEF ACCOUNTING OFFICER
Oct 02 '25
Sale
8.40
221
1,856
31,300
Thompson Travis Alvin
CHIEF ACCOUNTING OFFICER
Oct 03 '25
Sale
8.41
103
866
31,197
$38.56
price down icon 5.44%
$28.66
price down icon 0.62%
$105.98
price up icon 0.70%
$103.14
price down icon 0.20%
biotechnology ONC
$319.97
price down icon 3.73%
$189.70
price up icon 2.17%
大文字化:     |  ボリューム (24 時間):